Lack of efficacy of BRAF inhibitors in CRC (vs melanoma) was previously the best example of why an accurate tumor type diagnosis matters in metastatic disease. The BEACON trial put that example to rest. #BRAF #CRC $PFE

https://t.co/sFHAjFWUcq